KHTRF: AI 评分 56/100 — AI 分析 (4月 2026)

Knight Therapeutics Inc. is a specialty pharmaceutical company focused on developing, acquiring, and marketing pharmaceutical and consumer health products across Canada, Latin America, and internationally. The company offers a diverse portfolio of treatments across various therapeutic areas, including oncology, hematology, and infectious diseases.

Key Facts: AI Score: 56/100 Sector: Healthcare

公司概况

概要：

Knight Therapeutics Inc. operates as a specialty pharmaceutical company, marketing and distributing a diverse portfolio of pharmaceutical and consumer health products across Canada, Latin America, and internationally. With a focus on acquiring and developing niche treatments, Knight addresses unmet medical needs in various therapeutic areas, including oncology and infectious diseases, while navigating a competitive landscape.

KHTRF是做什么的？

Knight Therapeutics Inc., established in 2013 and headquartered in Montreal, Canada, is a specialty pharmaceutical company dedicated to acquiring, developing, and commercializing innovative pharmaceutical and consumer health products. The company operates across Canada, Latin America, and select international markets, focusing on niche therapeutic areas with unmet medical needs. Knight's portfolio includes treatments for oncology, hematology, infectious diseases, and other specialty areas. Knight's key products include Nerlynx for extended adjuvant breast cancer, Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma, and Pemigatinib for metastatic cholangiocarcinoma. The company also markets established products like Trelstar for advanced prostate cancer and Vidaza for myelodysplastic syndrome. Through strategic acquisitions and licensing agreements, Knight has built a diverse product pipeline and expanded its geographic reach. Knight Therapeutics also invests in other life science companies and venture capital funds, diversifying its business model beyond direct pharmaceutical sales. This approach allows Knight to participate in the broader healthcare ecosystem and potentially benefit from emerging technologies and therapies. The company aims to deliver sustainable growth by focusing on specialty products, strategic partnerships, and disciplined capital allocation.

KHTRF的投资论点是什么？

Knight Therapeutics Inc. presents a mixed investment case. The company's diverse product portfolio and geographic reach offer potential for revenue growth, particularly in the specialty pharmaceutical market. Key value drivers include the successful commercialization of recently acquired and in-licensed products, such as Nerlynx and Pemigatinib. The company's investments in life science companies and venture capital funds could provide additional upside. However, Knight's negative profit margin of -0.8% and high P/E ratio of -174.04 raise concerns about profitability. The company's reliance on acquisitions and licensing agreements also introduces risks related to integration and regulatory approvals. Investors should closely monitor Knight's ability to improve its financial performance and successfully execute its growth strategy.

KHTRF在哪个行业运营？

Knight Therapeutics Inc. operates in the specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Knight competes with both large multinational pharmaceutical companies and smaller specialty players. The company's focus on niche therapeutic areas and strategic partnerships allows it to differentiate itself in a crowded market. The global pharmaceuticals market is projected to reach $1.7 trillion by 2027, offering significant growth opportunities for companies like Knight.

Drug Manufacturers - Specialty & Generic

Healthcare

KHTRF有哪些增长机遇？

Expansion in Latin America: Knight has a significant opportunity to expand its presence in the Latin American pharmaceutical market. The region's growing population, increasing healthcare expenditure, and unmet medical needs create a favorable environment for pharmaceutical companies. Knight can leverage its existing infrastructure and partnerships to introduce new products and increase market share. The Latin American pharmaceutical market is projected to reach $100 billion by 2028.
Strategic Acquisitions and Licensing: Knight's business model relies on acquiring and licensing innovative pharmaceutical products. The company can continue to identify and acquire promising assets that complement its existing portfolio and address unmet medical needs. Strategic acquisitions can provide access to new markets, technologies, and revenue streams. The market for pharmaceutical licensing deals is expected to remain active, driven by the need for companies to replenish their product pipelines.
Development of Biosimilars: As patents for blockbuster drugs expire, Knight has the opportunity to develop and commercialize biosimilars. Biosimilars offer a lower-cost alternative to branded drugs and can capture a significant share of the market. Knight can leverage its expertise in pharmaceutical development and regulatory affairs to bring biosimilars to market. The global biosimilars market is projected to reach $35 billion by 2025.
Investment in Life Sciences Venture Capital: Knight's investments in life sciences venture capital funds provide exposure to emerging technologies and innovative therapies. These investments can generate financial returns and provide insights into future trends in the healthcare industry. Knight can leverage its venture capital investments to identify potential acquisition targets and licensing opportunities. The venture capital market for life sciences companies is expected to remain robust, driven by increasing investment in biotechnology and medical devices.
Focus on Specialty Products: Knight's focus on specialty pharmaceutical products allows it to target niche markets with high unmet medical needs. Specialty products typically command higher prices and offer greater profit margins compared to generic drugs. Knight can continue to develop and commercialize specialty products in areas such as oncology, hematology, and infectious diseases. The specialty pharmaceutical market is projected to grow at a faster rate than the overall pharmaceutical market.

Market capitalization of $0.43 billion reflects the company's current valuation in the specialty pharmaceutical market.
Negative P/E ratio of -174.04 indicates that the company is currently not profitable.
Gross margin of 38.8% demonstrates the company's ability to generate revenue above the cost of goods sold.
Beta of 0.17 suggests that the stock is less volatile than the overall market.
The company operates in Canada, Latin America, and internationally, providing geographic diversification.

KHTRF提供哪些产品和服务？

Develops and acquires pharmaceutical products.
In-licenses and out-licenses pharmaceutical products.
Markets and distributes pharmaceutical products.
Offers consumer health products.
Provides medical devices.
Finances other life science companies.
Invests in life sciences venture capital funds.

KHTRF如何赚钱？

Acquires or in-licenses rights to pharmaceutical products.
Markets and distributes these products in Canada, Latin America, and internationally.
Generates revenue through product sales.
Invests in other life science companies and venture capital funds for additional revenue streams.

Hospitals and clinics
Pharmacies
Patients
Healthcare providers

Specialty product portfolio targeting niche markets
Strategic partnerships and licensing agreements
Geographic diversification across Canada, Latin America, and international markets
Investments in life science companies and venture capital funds

什么因素可能推动KHTRF股价上涨？

Ongoing: Commercialization of Nerlynx for extended adjuvant breast cancer.
Ongoing: Expansion of Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma.
Ongoing: Development and launch of new pharmaceutical products.
Ongoing: Strategic acquisitions and licensing agreements to expand product portfolio.

KHTRF的主要风险是什么？

Potential: Competition from larger pharmaceutical companies.
Potential: Patent expirations and generic competition.
Potential: Regulatory changes and compliance costs.
Ongoing: Negative profit margin and high P/E ratio.
Ongoing: Risks associated with investing in OTC stocks.

KHTRF的核心优势是什么？

Diverse product portfolio across multiple therapeutic areas
Established presence in Canada and Latin America
Strategic partnerships and licensing agreements
Investments in life science companies and venture capital funds

KHTRF的劣势是什么？

Negative profit margin
High P/E ratio
Reliance on acquisitions and licensing agreements
Limited product pipeline compared to larger pharmaceutical companies

KHTRF有哪些机遇？

Expansion in Latin America
Development of biosimilars
Acquisition of new pharmaceutical products
Investment in emerging healthcare technologies

KHTRF面临哪些威胁？

Competition from larger pharmaceutical companies
Patent expirations
Regulatory changes
Economic downturns in key markets

KHTRF的竞争对手是谁？

Agenus Inc — Focuses on immuno-oncology products. — (AGYTF)
American Vanguard Corp — Develops and markets crop protection products. — (AVCTF)
BiondVax Pharmaceuticals Ltd — Develops universal influenza vaccines. — (BOVNF)
Clinigen Group PLC — Provides access to medicines. — (CLHLF)
Corcel PLC — Develops advanced battery technologies. — (CRLBF)

Key Metrics

MoonshotScore: 56/100

Company Profile

CEO: Samira Sakhia
Headquarters: Montreal, CA
Employees: 745
Founded: 2014

AI Insight

AI analysis pending for KHTRF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Knight Therapeutics Inc. do?

Knight Therapeutics Inc. is a specialty pharmaceutical company that focuses on acquiring, developing, and commercializing pharmaceutical products and consumer health products. The company operates in Canada, Latin America, and internationally, offering a diverse portfolio of treatments across various therapeutic areas, including oncology, hematology, and infectious diseases. Knight also invests in other life science companies and venture capital funds, diversifying its business model beyond direct pharmaceutical sales and expanding its reach within the healthcare ecosystem.

What do analysts say about KHTRF stock?

AI analysis is currently pending for KHTRF. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided at this time. Investors should consult with a financial advisor and conduct their own research before making any investment decisions. Further information will be available once the AI analysis is complete.

What are the main risks for KHTRF?

Knight Therapeutics Inc. faces several risks, including competition from larger pharmaceutical companies, patent expirations and generic competition, regulatory changes and compliance costs, and economic downturns in key markets. The company's negative profit margin and high P/E ratio also pose financial risks. As an OTC stock, KHTRF is subject to additional risks, such as limited financial disclosure, lower liquidity, and potential for fraud or manipulation. Investors should carefully consider these risks before investing.